Overview

• Amgen said Repatha achieved statistically and clinically significant reductions in a composite of cardiovascular death, heart attack, and the most common type of stroke, while withholding effect sizes until presentation.
• Vesalius-CV enrolled about 12,000 people with atherosclerosis or diabetes and elevated cholesterol, allowed background lipid therapy, and followed participants for a median of roughly 4.5 years.
• The findings support potential use beyond Repatha’s current secondary prevention label, which could expand the eligible patient population if regulators agree.
• Repatha generated $2.2 billion in 2024 revenue, with growth prospects tempered by expected Medicare price constraints around 2029 and possible biosimilar competition near 2030.
• Competitive pressure looms from an oral PCSK9 inhibitor from Merck that reported positive results earlier this year, whereas Repatha is administered by injection every two weeks.